Losartan treating podocyte injury induced by Ang II via downregulation of TRPC6 in podocytes

Objective: In this study, we investigated the molecule mechanisms of podocyte injury and proteinuria and the protective effects of losartan. Methods: This study set up three groups: a control group; an Ang II group (Ang II 10(-6) mol/l, Sigma); and a losartan group (losartan 10(-6) mol/l, Sigma). We used RT-PCR assay to detect TRPC6 mRNA expression, and Western blot to detect TRPC6 protein expression. Results: TRPC6 overexpression was the basic change of podocyte injury and proteinuria occurrence. Losartan can treat podocyte injury and proteinuria induced by Ang II via downregulation of TRPC6 in podocytes. Conclusion: These findings maybe provide an ideal drug target for the diagnosis and treatment of acquired glomerular diseases.